What is Zymeworks's G&A?

Zymeworks (ZYME) reported G&A of $15.07M in Q1 2026.

How has Zymeworks's G&A changed year-over-year?

Zymeworks's G&A decreased by 11.3% year-over-year, from $16.99M to $15.07M.

What is the long-term trend for Zymeworks's G&A?

Over 3 years (2022 to 2025), Zymeworks's G&A has grown at a -5.7% compound annual growth rate (CAGR), from $73.36M to $61.51M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Zymeworks ZYME G&A

G&A at other companies

AnaptysBio, Inc.ANAB

$26.2M+85.4%

Septerna, Inc.SEPN

$10.29M+50.0%

Maze Therapeutics, Inc. Common StockMAZE

$12.41M+58.6%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

Spyre Therapeutics, Inc.SYRE

$15.23M+27.5%

Summit TherapeuticsSMMT

$62.59M+302%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's G&A?: Zymeworks (ZYME) reported G&A of $15.07M in Q1 2026.
How has Zymeworks's G&A changed year-over-year?: Zymeworks's G&A decreased by 11.3% year-over-year, from $16.99M to $15.07M.
What is the long-term trend for Zymeworks's G&A?: Over 3 years (2022 to 2025), Zymeworks's G&A has grown at a -5.7% compound annual growth rate (CAGR), from $73.36M to $61.51M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.